Abstract
Before reaching the market, the last stage of development through which a new pharmaceutical compound must pass is regulatory review. This is one stage of the drug development process that is outside the direct control of the sponsoring company. Currently, both pharmaceutical companies and regulatory authorities are striving to increase the efficiency of the review process. For this reason, a study has been conducted to ascertain how long compounds are spending within this process.Data on review times for compounds approved between 1990 and 1995 in at least one of nine major pharmaceutical markets (Australia, Canada, France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States) have been studied. Analysis of these data has shown that review times are decreasing in the majority of markets. In 1995 the average review time was around two years in most countries, and in some cases, review times of six months were possible. There are still differences, however, in the time a compound will sp...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
